Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,934.00-1.36%ETH$2,406.06-2.96%GOLD$4,384.50+1.19%OIL$103.82-1.90%
Smart Investors Daily
JS

NASDAQ · JSPR

Jasper Therapeutics, Inc.

Healthcare · Biotechnology

$0.57

Down-$0.06 (-9.91%)

Updated Sep 16, 2026, 12:26 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
29.9M
P/E ratio
-0.43
Dividend yield
0.00%
52-week range
$0.32 – $2.69
Volume
402.56K
Avg. volume
1.49M

Price performance

JSPR price history

1M range · 20 trading sessions · Daily adjusted prices

JSPR closed at $0.57 after 20 trading sessions, down 23.99% for the selected period.

Last close
$0.57
Period change
-23.99%
Period low
$0.57
Period high
$0.75
Daily close
View OHLC price history
JSPR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$0.64$0.6438$0.5679$0.5701402.56K
Sep 14, 2026$0.66$0.6682$0.60$0.6328404.68K
Sep 11, 2026$0.6933$0.711$0.66$0.6603294.29K
Sep 10, 2026$0.69$0.73$0.69$0.7007208.01K
Sep 9, 2026$0.7009$0.7144$0.68$0.70160.35K
Sep 8, 2026$0.7389$0.74$0.6952$0.7094189.96K
Sep 4, 2026$0.67$0.71$0.6642$0.7086432.93K
Sep 3, 2026$0.693$0.7098$0.6534$0.6864364.61K
Sep 2, 2026$0.6878$0.72$0.68$0.7049380.35K
Sep 1, 2026$0.70$0.7113$0.6346$0.6976854.47K
Aug 31, 2026$0.7149$0.74$0.6545$0.7114388.44K
Aug 28, 2026$0.7095$0.7095$0.6601$0.6997267.42K
Aug 27, 2026$0.7065$0.7438$0.69$0.6992254.79K
Aug 26, 2026$0.714$0.7211$0.6916$0.718247.15K
Aug 25, 2026$0.7085$0.7398$0.6987$0.7202271.83K
Aug 24, 2026$0.73$0.7353$0.6735$0.7224354.24K
Aug 21, 2026$0.68$0.7357$0.675$0.716780.85K
Aug 20, 2026$0.7351$0.76$0.6777$0.69122.34M
Aug 19, 2026$0.744$0.8098$0.7201$0.7466294.28K
Aug 18, 2026$0.82$0.91$0.66$0.752M

Latest JSPR news

The latest Smart Investors Daily articles mentioning JSPR.

Stock researchCompany · Overview

JSPR research

Overview

Company profile and research snapshot.

Company profile

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$41.67
Implied upside
—
Analysts
—
JSPR recent ratings
DateFirmRatingTarget
Aug 12, 2026Piper SandlerOverweight—
May 15, 2026TD CowenHold—
May 15, 2026RBC CapitalSector Perform—
Apr 1, 2026Evercore ISI GroupOutperform—
Nov 11, 2025RBC CapitalSector Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY. H.C. Wainwright 28th Annual Global Investment ConferencePresentation Date/Time: Wednesda

Benzinga · Aug 14, 2026

Jasper Therapeutics Q2 EPS $(0.10) Beats $(0.26) Estimate

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.26) by 61.54 percent. This is a 94.25 percent increase over losses of $(1.74) per share

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By